Mark Holliday

机构：Medical Research Institute of New Zealand · ORCID：0000-0003-2344-6091

发表论文 66 篇 · 总被引 3237 次 · h-index 23

代表论文

• Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma (2019 · New England Journal of Medicine · 被引 470)
• Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis (2022 · The Lancet · 被引 336)
• Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial (2019 · The Lancet · 被引 282)
• Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial (2023 · The Lancet · 被引 134)
• Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial (2020 · The Lancet Respiratory Medicine · 被引 119)
• ICS-formoterol relieverversusICS and short-acting β2-agonist reliever in asthma: a systematic review and meta-analysis (2020 · ERJ Open Research · 被引 61)